TapewireFind a company

person · Reporting owner

CRUTCHFIELD BRADFORD

Disclosed activity across 1 company

Tapewire entity
124251
SEC CIK
0001246406

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

No relationships currently tracked through insider filings.

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

No balances currently tracked through insider filings.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

10x Genomics, Inc.

Report date July 29, 2022 · Filed August 25, 2022

Section 16 reporting ended · disclosed 2022-08-25. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
November 02, 2020 Filed Nov 4, 2020 21:33 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 1,500 $135.29 $202,938.00
Disclosure

SEC source: 0001209191-20-057066 · doc4.xml · nonDerivative · entry 2

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,967

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $134.63 to $139.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
November 02, 2020 Filed Nov 4, 2020 21:33 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 10,504 $1.16 $12,184.64
Disclosure

SEC source: 0001209191-20-057066 · doc4.xml · nonDerivative · entry 1

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,467

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 16:02 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 17,000 $0.00 Strike: $1.16 $0.00
Disclosure

SEC source: 0001209191-20-053571 · doc4.xml · derivative · entry 6

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 664,000

Underlying: Class A Common Stock · 17,000 shares

Expires 2027-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F5 · derivative.exercise_date: This option, originally for 800,000 shares, of which 136,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 16:02 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 300 $126.88 $38,064.00
Disclosure

SEC source: 0001209191-20-053571 · doc4.xml · nonDerivative · entry 5

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 963

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 16:02 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 3,475 $125.99 $437,821.85
Disclosure

SEC source: 0001209191-20-053571 · doc4.xml · nonDerivative · entry 4

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,263

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $125.81 to $126.13. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 16:02 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 10,725 $125.48 $1,345,731.17
Disclosure

SEC source: 0001209191-20-053571 · doc4.xml · nonDerivative · entry 3

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,738

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $124.81 to $125.80. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 16:02 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 2,500 $124.26 $310,643.00
Disclosure

SEC source: 0001209191-20-053571 · doc4.xml · nonDerivative · entry 2

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,463

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $123.76 to $124.72. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 16:02 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 17,000 $1.16 $19,720.00
Disclosure

SEC source: 0001209191-20-053571 · doc4.xml · nonDerivative · entry 1

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,963

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
September 02, 2020 Filed Sep 3, 2020 17:58 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 3,224 $0.00 Strike: $1.16 $0.00
Disclosure

SEC source: 0001209191-20-049517 · doc4.xml · derivative · entry 13

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 681,000

Underlying: Class A Common Stock · 3,224 shares

Expires 2027-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F11 · derivative.exercise_date: This option, originally for 800,000 shares, of which 119,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
September 02, 2020 Filed Sep 3, 2020 17:58 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 50 $114.89 $5,744.50
Disclosure

SEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 11

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 963

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
September 02, 2020 Filed Sep 3, 2020 17:58 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 150 $114.10 $17,115.00
Disclosure

SEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 10

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,013

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F9 · price: This transaction was executed in multiple trades at prices ranging from $113.82 to $114.57. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
September 02, 2020 Filed Sep 3, 2020 17:58 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 528 $113.18 $59,758.99
Disclosure

SEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 9

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,163

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F8 · price: This transaction was executed in multiple trades at prices ranging from $112.82 to $113.655. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
September 02, 2020 Filed Sep 3, 2020 17:58 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 1,496 $112.32 $168,034.61
Disclosure

SEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 8

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,691

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F7 · price: This transaction was executed in multiple trades at prices ranging from $111.80 to $112.74. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
September 02, 2020 Filed Sep 3, 2020 17:58 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 1,000 $111.33 $111,327.30
Disclosure

SEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 7

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,187

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F6 · price: This transaction was executed in multiple trades at prices ranging from $110.79 to $111.72. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
September 02, 2020 Filed Sep 3, 2020 17:58 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 3,224 $1.16 $3,739.84
Disclosure

SEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 6

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,187

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
September 01, 2020 Filed Sep 3, 2020 17:58 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 13,776 $0.00 Strike: $1.16 $0.00
Disclosure

SEC source: 0001209191-20-049517 · doc4.xml · derivative · entry 12

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 684,224

Underlying: Class A Common Stock · 13,776 shares

Expires 2027-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F10 · derivative.exercise_date: This option, originally for 800,000 shares, of which 115,776 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
September 01, 2020 Filed Sep 3, 2020 17:58 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 500 $115.41 $57,704.40
Disclosure

SEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 5

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 963

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $115.29 to $115.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
September 01, 2020 Filed Sep 3, 2020 17:58 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 4,789 $114.65 $549,039.22
Disclosure

SEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 4

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,463

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $114.27 to $115.25. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
September 01, 2020 Filed Sep 3, 2020 17:58 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 5,887 $113.82 $670,066.58
Disclosure

SEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 3

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,252

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $113.26 to $114.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
September 01, 2020 Filed Sep 3, 2020 17:58 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 2,600 $112.92 $293,593.04
Disclosure

SEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 2

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,139

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $112.25 to $113.23. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
September 01, 2020 Filed Sep 3, 2020 17:58 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 13,776 $1.16 $15,980.16
Disclosure

SEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 1

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,739

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
August 03, 2020 Filed Aug 5, 2020 16:51 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 17,000 $0.00 Strike: $1.16 $0.00
Disclosure

SEC source: 0001209191-20-045147 · doc4.xml · derivative · entry 5

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 698,000

Underlying: Class A Common Stock · 17,000 shares

Expires 2027-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F6 · derivative.exercise_date: This option, originally for 800,000 shares, of which 102,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
August 03, 2020 Filed Aug 5, 2020 16:51 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 1,200 $100.72 $120,858.96
Disclosure

SEC source: 0001209191-20-045147 · doc4.xml · nonDerivative · entry 4

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 963

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $100.23 to $101.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
August 03, 2020 Filed Aug 5, 2020 16:51 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 8,342 $99.47 $829,817.95
Disclosure

SEC source: 0001209191-20-045147 · doc4.xml · nonDerivative · entry 3

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,163

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $99.19 to $100.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
August 03, 2020 Filed Aug 5, 2020 16:51 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 7,458 $98.94 $737,929.57
Disclosure

SEC source: 0001209191-20-045147 · doc4.xml · nonDerivative · entry 2

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,505

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $98.19 to $99.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
August 03, 2020 Filed Aug 5, 2020 16:51 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 17,000 $1.16 $19,720.00
Disclosure

SEC source: 0001209191-20-045147 · doc4.xml · nonDerivative · entry 1

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,963

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · balance_after: Includes 963 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan on May 14, 2020.

Read SEC document
July 01, 2020 Filed Jul 2, 2020 20:21 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 17,000 $0.00 Strike: $1.16 $0.00
Disclosure

SEC source: 0001209191-20-040739 · doc4.xml · derivative · entry 5

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 715,000

Underlying: Class A Common Stock · 17,000 shares

Expires 2027-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F5 · derivative.exercise_date: This option, originally for 800,000 shares, of which 85,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
July 01, 2020 Filed Jul 2, 2020 20:21 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 500 $88.73 $44,366.00
Disclosure

SEC source: 0001209191-20-040739 · doc4.xml · nonDerivative · entry 4

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $88.50 to $88.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
July 01, 2020 Filed Jul 2, 2020 20:21 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 8,900 $87.94 $782,707.83
Disclosure

SEC source: 0001209191-20-040739 · doc4.xml · nonDerivative · entry 3

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $87.49 to $88.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
July 01, 2020 Filed Jul 2, 2020 20:21 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 7,600 $87.11 $662,061.84
Disclosure

SEC source: 0001209191-20-040739 · doc4.xml · nonDerivative · entry 2

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,400

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $86.49 to $87.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
July 01, 2020 Filed Jul 2, 2020 20:21 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 17,000 $1.16 $19,720.00
Disclosure

SEC source: 0001209191-20-040739 · doc4.xml · nonDerivative · entry 1

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
June 01, 2020 Filed Jun 3, 2020 17:53 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 17,000 $0.00 Strike: $1.16 $0.00
Disclosure

SEC source: 0001209191-20-034163 · doc4.xml · derivative · entry 8

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 732,000

Underlying: Class A Common Stock · 17,000 shares

Expires 2027-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F8 · derivative.exercise_date: This option, originally for 800,000 shares, of which 68,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
June 01, 2020 Filed Jun 3, 2020 17:53 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 2,000 $81.92 $163,844.00
Disclosure

SEC source: 0001209191-20-034163 · doc4.xml · nonDerivative · entry 7

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F7 · price: This transaction was executed in multiple trades at prices ranging from $81.74 to $82.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
June 01, 2020 Filed Jun 3, 2020 17:53 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 4,900 $81.39 $398,801.20
Disclosure

SEC source: 0001209191-20-034163 · doc4.xml · nonDerivative · entry 6

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F6 · price: This transaction was executed in multiple trades at prices ranging from $80.74 to $81.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
June 01, 2020 Filed Jun 3, 2020 17:53 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 2,500 $80.05 $200,132.00
Disclosure

SEC source: 0001209191-20-034163 · doc4.xml · nonDerivative · entry 5

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,900

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $79.66 to $80.65. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
June 01, 2020 Filed Jun 3, 2020 17:53 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 2,500 $79.14 $197,845.00
Disclosure

SEC source: 0001209191-20-034163 · doc4.xml · nonDerivative · entry 4

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,400

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $78.65 to $79.64. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
June 01, 2020 Filed Jun 3, 2020 17:53 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 3,400 $78.06 $265,419.64
Disclosure

SEC source: 0001209191-20-034163 · doc4.xml · nonDerivative · entry 3

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,900

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $77.62 to $78.46. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
June 01, 2020 Filed Jun 3, 2020 17:53 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 1,700 $77.17 $131,182.03
Disclosure

SEC source: 0001209191-20-034163 · doc4.xml · nonDerivative · entry 2

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,300

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $76.60 to $77.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
June 01, 2020 Filed Jun 3, 2020 17:53 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 17,000 $1.16 $19,720.00
Disclosure

SEC source: 0001209191-20-034163 · doc4.xml · nonDerivative · entry 1

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
May 01, 2020 Filed May 5, 2020 16:51 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 17,000 $0.00 Strike: $1.16 $0.00
Disclosure

SEC source: 0001209191-20-027168 · doc4.xml · derivative · entry 6

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 749,000

Underlying: Class A Common Stock · 17,000 shares

Expires 2027-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F6 · derivative.exercise_date: This option, originally for 800,000 shares, of which 51,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
May 01, 2020 Filed May 5, 2020 16:51 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 300 $79.23 $23,769.00
Disclosure

SEC source: 0001209191-20-027168 · doc4.xml · nonDerivative · entry 5

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F5 · price: This transaction was executed in multiple trades at prices ranging from $79.20 to $79.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
May 01, 2020 Filed May 5, 2020 16:51 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 4,200 $78.66 $330,370.32
Disclosure

SEC source: 0001209191-20-027168 · doc4.xml · nonDerivative · entry 4

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $78.16 to $79.12. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
May 01, 2020 Filed May 5, 2020 16:51 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 3,695 $77.57 $286,633.71
Disclosure

SEC source: 0001209191-20-027168 · doc4.xml · nonDerivative · entry 3

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,500

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $77.13 to $78.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
May 01, 2020 Filed May 5, 2020 16:51 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 8,805 $76.63 $674,696.33
Disclosure

SEC source: 0001209191-20-027168 · doc4.xml · nonDerivative · entry 2

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,195

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $76.13 to $77.09. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
May 01, 2020 Filed May 5, 2020 16:51 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionClass A Common Stock 17,000 $1.16 $19,720.00
Disclosure

SEC source: 0001209191-20-027168 · doc4.xml · nonDerivative · entry 1

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

Read SEC document
April 21, 2020 Filed Apr 23, 2020 16:44 UTC 10x Genomics, Inc. TXG · Entity 2172 GrantStock Option (right to buy) · Derivative 90,667 $0.00 Strike: $74.58 $0.00
Disclosure

SEC source: 0001209191-20-025437 · doc4.xml · derivative · entry 1

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,667

Underlying: Class A Common Stock · 90,667 shares

Expires 2030-04-21

F1 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2020 and each month thereafter, subject to the reporting person continuing as a service provider through each such date.

Read SEC document
April 01, 2020 Filed Apr 3, 2020 17:10 UTC 10x Genomics, Inc. TXG · Entity 2172 Exercise / conversionStock Option (right to buy) · Derivative 17,000 $0.00 Strike: $1.16 $0.00
Disclosure

SEC source: 0001209191-20-023278 · doc4.xml · derivative · entry 5

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 766,000

Underlying: Class A Common Stock · 17,000 shares

Expires 2027-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F5 · derivative.exercise_date: This option, originally for 800,000 shares, of which 34,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Read SEC document
April 01, 2020 Filed Apr 3, 2020 17:10 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 400 $59.62 $23,848.12
Disclosure

SEC source: 0001209191-20-023278 · doc4.xml · nonDerivative · entry 4

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F4 · price: This transaction was executed in multiple trades at prices ranging from $59.38 to $59.80. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
April 01, 2020 Filed Apr 3, 2020 17:10 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 7,789 $58.33 $454,318.35
Disclosure

SEC source: 0001209191-20-023278 · doc4.xml · nonDerivative · entry 3

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $58.02 to $58.96. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document
April 01, 2020 Filed Apr 3, 2020 17:10 UTC 10x Genomics, Inc. TXG · Entity 2172 SaleClass A Common Stock 8,811 $57.75 $508,839.66
Disclosure

SEC source: 0001209191-20-023278 · doc4.xml · nonDerivative · entry 2

CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,189

F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $57.02 to $58.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.